Brought to you by 
Bard licenses AAA endoluminal graft device from Endologix
03 Sep 1999
Executive Summary
CR Bard has licensed exclusive European and Australian distribution rights to endovascular abdominal aortic aneurysms (AAAs) surgical device start-up, Endologix's minimally invasive endoluminal graft (ELG) for treating AAAs or weakening of the aortic wall. As part of the agreement, Bard has optioned the right to acquire all Endologix outstanding shares at an undisclosed pre-set price by the end of 2000.
Deal Industry
-
Medical Devices
- Implantable Devices
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bard licenses AAA endoluminal graft device from Endologix
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice